Cargando…

Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?

5-Loxin(® )is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in...

Descripción completa

Detalles Bibliográficos
Autor principal: Dougados, Maxime
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592778/
https://www.ncbi.nlm.nih.gov/pubmed/18828886
http://dx.doi.org/10.1186/ar2490
_version_ 1782161578872799232
author Dougados, Maxime
author_facet Dougados, Maxime
author_sort Dougados, Maxime
collection PubMed
description 5-Loxin(® )is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound.
format Text
id pubmed-2592778
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25927782008-12-03 Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect? Dougados, Maxime Arthritis Res Ther Editorial 5-Loxin(® )is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound. BioMed Central 2008 2008-09-19 /pmc/articles/PMC2592778/ /pubmed/18828886 http://dx.doi.org/10.1186/ar2490 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Editorial
Dougados, Maxime
Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
title Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
title_full Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
title_fullStr Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
title_full_unstemmed Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
title_short Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
title_sort lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592778/
https://www.ncbi.nlm.nih.gov/pubmed/18828886
http://dx.doi.org/10.1186/ar2490
work_keys_str_mv AT dougadosmaxime lipooxygenaseinhibitioninosteoarthritisapotentialsymptomaticanddiseasemodifyingeffect